GD2

GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans.

The relatively tumor specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.

References

2. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. Ahmed M, Cheung NK. FEBS Lett. 2014 Jan 21;588(2):288-97

3. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Cheung NK, Dyer MA. Nat Rev Cancer. 2013 Jun;13(6):397-411

This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/GD2

Latest News for: gd2

Edit

Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody

Public Technologies 11 Dec 2018

Food and Drug Administration ('FDA') has cleared the Investigational New Drug ('IND') application for a humanized bispecific GD2 antibody ... The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates-naxitamab and omburtamab-which target tumors that express GD2 and B7-H3, respectively....

Edit

Bispecific GD2 Antibody In Vivo Data to be Presented at ASH

Public Technologies 01 Nov 2018

Jeong A Park from the Department of Pediatrics of Memorial Sloan-Kettering Cancer Center (MSK) will present preclinical data from the Company's bispecific GD2 antibody in a poster presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA on December 3, 2018, at 9.00 PM Eastern....

Edit

MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on ...

The Daily Times 17 May 2018

[STK] NASDAQ-SMALL.MBVX ... ....

Edit

MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma

Public Technologies 17 May 2018

9,856,324 by the United States Patent and Trademark Office (USPTO) for a patent titled, 'HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2.' ... Additional disease targets for anti-GD2 antibodies include sarcoma, melanoma, and neuroblastoma....

Edit

Apeiron Announces Publication of Clinical Data with Anti-GD2&#160Antibody&#160Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

MENA FN 18 Dec 2017

(MENAFN Editorial) VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successf... ....

Edit

Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

Pharmiweb 18 Dec 2017

Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refrac... ....

Edit

Apeiron Announces Publication of Clinical Data with Anti-GD2�Antibody�Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

Nasdaq Globe Newswire 18 Dec 2017

VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal antibody field. Dr ... ....

Edit

Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 ...

PR Newswire 03 Oct 2017

SAN DIEGO, Oct. 3, 2017 /PRNewswire/ --MabVax Therapeutics Holdings, Inc. (Nasdaq. MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the ... ....

Edit

Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress

Public Technologies 03 Oct 2017

Jude Children's Hospital, MabVax is investigating the targeting specificity of two HuMab-GD2 ganglioside antibodies ... In vitro profiling shows that both antibodies are readily internalized and both antibodies accumulate in GD2 positive patient-derived osteosarcoma xenografts within 48 hours....